For pharmaceutical companies, the next phase of growth will depend less on price reductions and more on improving: Patient persistence Physician confidence Access and affordability Awareness of obesity as a chronic disease Convenient treatment options, particularly oral GLP-1 therapies The companies that solve these barriers are likely to shape the next decade of India's metabolic disease market
Berry, DO 2 , Aamir-Ali Shaikh, BS, MPH 3 , Hezborn Magacha, MD 2 , Venkata Pulivarthi, MD 2 1East Tennessee State University, Kingsport, TN
The FDA maintains the boxed warning because proving a negative, proving that something definitively does NOT cause cancer, requires decades of surveillance data
With extensive experience and a deep understanding of GLP-1 medications, we provide top-notch care tailored to your needs
However, its essential to remember that these treatments are not standalone solutions but augmentations to the necessary dietary changes and regular physical activity